quaratusugene ozeplasmid + atezolizumab

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Small Cell Lung Cancer Extensive Stage

Conditions

Small Cell Lung Cancer Extensive Stage

Trial Timeline

May 9, 2024 → Aug 1, 2027

NCT ID

NCT05703971

About quaratusugene ozeplasmid + atezolizumab

quaratusugene ozeplasmid + atezolizumab is a phase 1/2 stage product being developed by Genprex for Small Cell Lung Cancer Extensive Stage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05703971. Target conditions include Small Cell Lung Cancer Extensive Stage.

What happened to similar drugs?

20 of 20 similar drugs in Small Cell Lung Cancer Extensive Stage were approved

Approved (20) Terminated (2) Active (0)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅Pemetrexed + CarboplatinEli LillyApproved

✅pemetrexedEli LillyApproved

✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved

✅DurvalumabAstraZenecaApproved

✅Gefitinib + DocetaxelAstraZenecaApproved

✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05703971	Phase 1/2	Recruiting	May 9, 2024	Aug 1, 2027	Small Cell Lung Cancer Extensive Stage

Competing Products

20 competing products in Small Cell Lung Cancer Extensive Stage

See all competitors

Product	Company	Stage	Hype Score
mRNA-1769	Moderna	Phase 2	0
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	40
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Selpercatinib	Eli Lilly	Pre-clinical	26
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	40
NBTXR3	Nanobiotix	Phase 1/2	33
Pemetrexed	Eli Lilly	Pre-clinical	26
pemetrexed + erlotinib	Eli Lilly	Phase 2	35
LY3295668 Erbumine	Eli Lilly	Phase 1	29
FYB206 + FYB206 + Keytruda	Formycon AG	Phase 3	22
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	37
pemetrexed + cisplatin	Eli Lilly	Phase 2	27
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	35
Cetuximab	Eli Lilly	Phase 1	29
pemetrexed + docetaxel	Eli Lilly	Phase 3	40
enzastaurin + pemetrexed + docetaxel + carboplatin	Eli Lilly	Phase 2	35
PemCarbo + Pem only	Eli Lilly	Phase 3	36
TNG456 + abemaciclib	Eli Lilly	Phase 1/2	39